BRAF and melanoma: Since the US Food and Drug Administration (FDA) granted approval for ipilimumab in 2011—marking the introduction of the first immune checkpoint inhibitor to enhance survival in advanced cases (Teixido et al., 2021; Hodi et al., 2010)—and vemurafenib, which is the first in its class as a BRAF tyrosine kinase inhibitor derived from the v-raf murine sarcoma viral oncogene homolog B1, there has been a notable decline in melanoma mortality (Sosman et al., 2012; Chapman et al., 2011).